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LETTERS
Seroepidemiology 
of Saffold 
Cardiovirus 
Type 2
To the Editor: Saffold virus 
(SAFV) is a new human virus 
belonging to the genus Cardiovirus 
of the family Picornaviridae (1–6). 
The virus has also been named human 
Theiler’s-like cardiovirus (4). To 
date, 8 SAFV genotypes are known, 
based on molecular variation in the 
P1 region, which codes for the viral 
capsid (5). SAFVs are detected in 
respiratory and fecal samples from 
infants and children <6 years of age. 
The virus is generally detected at low 
frequency (0.5%–3%) in the general 
population, but in Afghanistan and 
Pakistan higher incidences have been 
reported (10%–12%) (5). Detection is 
mainly based on molecular techniques 
because virus isolation is cumbersome. 
Other than gastroenteritis, no clear 
disease manifestations are known (1–
8), although recently, researchers in 
Japan have suggested that for a select 
group of children, SAFV infection 
may cause pharyngitis and tonsillitis 
(7). In rodents, however, cardioviruses 
are serious pathogens that can cause 
myocarditis, meningoencephalitis, 
and pancreatitis.
Previously, we have shown that 
SAFV-3 infections are ubiquitous and 
are transmitted early in life (6). This 
conclusion was based on antibody 
testing by virus neutralization, a highly 
specifi c test that can discriminate 
serotypes within a single species, 
but formal proof for existence of 
serotypes was lacking. Extrapolated 
to other genotypes, the fi nding would 
indicate a high infection rate for 
SAFVs, which is at odds with the low 
detection frequency reported in most 
studies. Most SAFV-2 isolates, from 
our laboratory and others, grow poorly 
in cell culture, which hampers reading 
of neutralization. Recently, however, a 
SAFV-2 strain was isolated in Finland 
that grows well in HeLa cells and 
shows clear cytopathic effects (SAFV-
2-FIN2008, GenBank accession no. 
FR682076; S. Blomgvist et al., unpub. 
data). This strain enabled us to set up 
a virus neutralization test similar to 
that described for SAFV-3 (6). For 
comparison, we used strain SAFV-
3(NL2007) (GenBank accession no. 
FM207487), which was isolated in 
Nijmegen (6). The virus neutralization 
test was performed on HeLa cells with 
100 TCID50 of virus per serum dilution. 
Virus–serum mixtures were incubated 
for 1 hour at 37°C and overnight at 7°C 
to stabilize virus–antibody complexes 
(6). Human serum samples submitted 
previously were tested by using 
3-fold dilution steps and duplicate 
testing (6). The results are presented 
in the Table. A low seroprevalence 
was found for SAFV-2 and SAFV-
3 at 9 months of age, which is at the 
nadir of immunoglobulin G levels 
in infants. At the age of 24 months, a 
high seroprevalence of antibodies was 
found in the Netherlands for SAFV-2 
and -3, pointing to early acquisition of 
infection with both strains. In Finland, 
the seroprevalence for SAFV-2 and -3 
was lower in young children, which 
suggests somewhat lower infection rate 
similar to what has been reported for 
enteroviruses (9). A high seroprevalence 
of 97%–100% was found in persons >4 
years of age in Cameroon, Indonesia, 
and the Netherlands (Table). A high 
prevalence of SAFV-2 antibodies was 
recently also reported in blood donors 
from the United States (8). Thus, the 
seroepidemiology of SAFV-2 is similar 
to that of SAFV-3. As depicted in the 
last 3 columns of the Table, on several 
occasions serum samples independently 
neutralized either SAFV-2 or SAFV-3, 
which suggests that the viruses behave 
as different serotypes.
In conclusion, SAFV-2 and 
SAFV-3 show an almost identical 
epidemiologic pattern with infection 
acquired early in life and with a high 
seroprevalence in different continents. 
The outcome is concordant with 
universal occurrence of infection 
by both genotypes. Because several 
times there was a clear discrepancy 
between antibody titers against one 
or the other of the 2 genotypes, we 
conclude that they behave as separate 
serotypes, although weak cross-
reactivity (below the detection limit of 
1:15) cannot be excluded. Accepting 
that SAFV genotypes correspond 
with existence of different serotypes, 
the infection rate in the fi rst years 
of life must be quite high, similar 
to that for human parechoviruses 
and enteroviruses, which are found 
in 15%–18% of stool samples from 
children <5 years of age (10). The 
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Table. SAFV-neutralizing antibodies in blood samples from humans of different ages and from different geographic regions* 
Country 
No.
samples 
Patient
age†
Years 
collected 
No. (%) samples 
SAFV-2 pos‡ SAFV-3 pos‡ SAFV pos§ 
SAFV-2 pos + 
SAFV-3 neg 
SAFV-2 neg + 
SAFV-3 pos 
Netherlands 29 9 mo 2006–2007 15 (52) 4 (14) 15 (52) 11 0
Netherlands 26 24 mo 2006–2007 21 (81) 20 (77) 25 (96) 5 4
Netherlands 30 18–39 y 2004 30 (100) 29 (97) 30 (100) 1 0
Finland 30 2–2.5 y 1997–1998 10 (33) 21 (70) 24 (80) 3 14
Cameroon 29 5–15 y 1997 28 (97) 28 (97) 29 (100) 1 1
Indonesia 30 4–40 y 1997–1998 30 (100) 30 (100) 30 (100) 0 0
*SAFV, Saffold virus; pos, positive; neg, negative.  
†Samples were collected from patients at this age or within this age range. 
‡Titer >15. 
§Cumulative positive for antibodies against SAFV-2 and/or SAFV-3. 
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low SAFV detection rate remains 
thereby diffi cult to explain. 
The outcome can be explained 
by a short duration of virus excretion 
in stool, which, however, is unlikely 
for an infection spreading by the 
fecal–oral route. Alternatively, it may 
be that the virus is unstable in stool 
and rapidly degrades, such that fecal 
samples are inadequate for diagnosis 
of the infection. Other specimens, 
however, such as respiratory samples, 
yielded also low numbers of positive 
fi ndings (4). Remarkably, the study 
with a high prevalence of positive 
stool samples made use of primers 
selected in a conserved region of 2C 
helicase (5), whereas other studies 
used primers in the 5′ noncoding 
region (3,4). Hence, a difference in 
sensitivity between the different PCRs 
may be responsible for the discrepancy 
between seroepidemiology and the 
low diagnostic yield by PCR. This 
discrepancy, however, awaits further 
investigation.
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Alkhurma 
Hemorrhagic Fever 
in Travelers 
Returning from 
Egypt, 2010
To the Editor: The report of 2 
visitors from Italy being infected by 
Alkhurma hemorrhagic fever virus 
(AHFV) in southeastern Egypt near 
the border with Sudan (1) provides 
useful data to help clarify the 
evolutionary origin of these tick-borne 
fl aviviruses. AHFV was fi rst isolated 
in Saudi Arabia and is associated with 
camel ticks (2). It is a genetically close 
relative of Kyasanur Forest disease 
virus, which was fi rst isolated in 
India in 1957. Following the original 
isolation of Kyasanur Forest disease 
virus, there was no clear explanation 
for its apparent isolation in the 
Indian forests. Indeed, its subsequent 
discovery in southern China (3) 
suggested that migratory birds might 
carry the infected ticks to or from that 
region.
The most likely explanation 
for these outbreaks of hemorrhagic 
disease now begins to fi t a pattern 
that can be interpreted in terms of the 
diseases’ evolutionary origin in Africa. 
Thousands of animals are annually 
transported from Africa and other 
countries to Mecca, Saudi Arabia, to 
meet the human demand for food and 
transport during the Hajj. Many of these 
animals, including camels, are infested 
with ticks that may carry AHFV 
and thus provide the source of this 
human infectious agent. Phylogenetic 
evidence had previously suggested that 
the tick-borne encephalitic fl avivirus 
serocomplex originated in Africa 
and gradually evolved and dispersed 
across the Northern Hemisphere of 
the Old World (4,5). This concept is 
totally consistent with the discoveries 
of AHFV in Saudi Arabia and now in 
southeastern Egypt. Thus, Africa is 
a likely source of infected ticks that 
are regularly moved between Africa 
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